Stock Price

A struggling medtech firm and an AI drug developer merge. It's not just a deal; it's a new blueprint for innovation, funded by high-risk capital.

Recent SEC filings link powerhouse investor Citadel to streaming upstart FreeCast. But as we peel back the layers, a story of high-risk, high-reward emerges.

Singapore-based Ohmyhome faces a Nasdaq delisting notice. With 180 days to recover, can its radical pivot to digital marketing save it from the brink?

An institutional investor’s decisive move spotlights a €205M valuation gap in the Addiko Bank takeover, raising critical questions about M&A fairness.

Intuit faces a class-action lawsuit after a 20% stock drop. Allegations of misleading statements and $41M in insider sales put a spotlight on executive accountability.

A shareholder lawsuit against Planet Fitness alleges misleading growth plans led to a 31% stock crash, raising questions about corporate transparency.

A $17.5M write-down and a shareholder lawsuit reveal a critical lesson for tech firms: production capacity must align with market demand, or investors will pay the price.

Transcat's upcoming earnings are more than just numbers; they're a barometer for the life sciences and aerospace sectors. Can its M&A strategy sustain growth?

With its MASH drug Rezdiffra a certified blockbuster, Madrigal's upcoming Q2 report will reveal if its meteoric rise can be sustained against new rivals.

The UK SME lender reports a 50% revenue jump and soaring profits, crediting its AI platform and new FlexiPay and Card products for defying market headwinds.

As investors await Multitude AG’s mid-year results, a look at recent performance and a shifting European regulatory landscape reveals a story of strategic recalibration.

AST SpaceMobile secured $1 billion via complex convertible notes to accelerate its global network, a strategic bet that spooks investors with dilution fears.

As Applied Digital prepares its year-end report, all eyes are on the data center builder. Can it sustain its explosive growth and justify its massive bets on AI?

As Celldex nears pivotal data for its lead drug, the planned retirement of its long-serving CFO marks a strategic pivot toward becoming a commercial powerhouse.

Borealis Foods launched its high-protein Chef Woo noodles in Costco, a savvy move to tap the 'Ozempic Effect.' But can one product's promise save a company facing dire financial headwinds?

A Chinese firm aims to revolutionize cancer treatment with a cloud-based AI system, but faces a tough fight against industry giants and its own financial reality.

After a 90% stock crash since its IPO, activist firm Randian Capital is demanding a strategic review, questioning leadership and industry headwinds.

Entegris's latest dividend is more than a payout; it's a signal of deep financial health and strategic positioning in the critical semiconductor industry.

Worthington Steel moves to take full control of German metals giant Kloeckner & Co, launching a delisting offer that puts shareholders at a crossroads.

Rubico Inc. is selling its luxury megayacht to double down on oil tankers. A look at whether this strategic pivot can overcome a history of investor doubt.